💊

Breyanzi

lisocabtagene maraleucel

Lymphome à grandes cellules B, diffus ; Lymphome folliculaire ; Néoplasmes médiastinaux

✅ Autorisé Thérapie avancée

✅

Aucune alerte active

Ce médicament ne fait l'objet ni de pénuries en cours, ni de lettres de sécurité, ni de rappels.

À quoi ça sert

Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.   Breyanzi is indicated for the treatment of adult patients with relapsed or refractory DLBCL, PMBCL and FL3B, after two or more lines of systemic therapy.  Breyanzi is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.   Breyanzi is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor. 

⚠️ Sécurité des patients

Page officielle de l'EMA

https://www.ema.europa.eu/en/medicines/human/EPAR/breyanzi